Merkliste 
 1 Ergebnisse 
 
1

A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 ..:

Rubin, David ; Lee, Scott D ; Flores, Lucky...
Inflammatory Bowel Diseases.  29 (2023)  Supplement_1 - p. S77-S78 , 2023